Drug Trial Radar · NCT04049760
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Oct 11, 2019
Primary completion
Nov 29, 2024
Study completion Nov 29, 2024
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects \> 12 Years of Age With Fabry Disease and Amenable GLA Variants
Conditions
- Fabry Disease
Interventions
migalastat HCl 150 mgDrug
migalastat HCl 150 mg capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study DrugTime frame: Entire study
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of South Florida
Tampa, Florida
The Emory Clinic
Atlanta, Georgia
University of Minnesota Masonic Children's Hospital and Clinics
Minneapolis, Minnesota
Cincinnati Children's Hospital
Cincinnati, Ohio
Lysosomal & Rare Disorders Research & Treatment Center
Fairfax, Virginia
Royal Free London NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.